Adult Dosing
Pulmonary arterial hypertension
- Initial dose: Start 18 mcg (3 breaths) nebulization qid, 3 breath not tolerated, reduce 1-2 breath
- Maintenance Dose: Increase by 3 breaths/dose q1-2 wks , MAX: 9 breaths qid
Note:
- 1 breath = 6 mcg
- The interval between two doses should be approximately 4 hours
Pediatric Dosing
- Safety and efficacy in pediatric patient have not been established
[Outline]
- Safety and effectiveness in underlying lung disease (such as asthma or chronic obstructive pulmonary disease) has not been established. Monitor carefully the patients with acute pulmonary infections patient
- Patients with hepatic and renal insufficiency are at increased risk of dose-dependent adverse reactions, slowly titer the dose
- Increased risk of bleeding due to platelet aggregation inhibition
- Increased risk of symptomatic hypotension in patients wtih low systemic arterial pressure or receiving blood pressure lowering agents
- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Asthma
- COPD
- Acute pulmonary infection
- Hypotension
- Hypovolemia
- Bleeding tendencies
Pregnancy Category:B
Breastfeeding: Safety unknown. Excretion of treprostinil in human milk or systemic absorption after ingestion is unknown, however manufacturer advises to use cautiously while administering nursing mother as many drugs are excreted in milk.
